A dog model using an implanted system for protracted hepatic arterial chemotherapy.
A model for hepatic arterial chemotherapy studies using large dogs and an implantable infusion pump has been developed. Using this technique near complete perfusion (greater than 90%) of the liver can be achieved in vivo as determined by hepatic arterial perfusion scintigraphy with technitium 99m macroaggregated albumin. The system is reliable and has been in use for a total of 1353 days (mean of 104 days, range 52-239) in 13 dogs. Pump implantation causes no apparent acute liver damage based on pre- and post-operative alkaline phosphatase and serum glutamic-pyruvic transaminase determinations and does not affect the general mobility or behavior of the animals. Careful placement of the catheter and attention to the physicochemical properties of the solutions loaded are factors contributing to the success of the model. The model permits comprehensive preclinical pharmacokinetic and toxicologic studies of new or preexistent chemotherapeutic agents in the same device that will be used for later administration in human subjects. By providing the means to examine and develop new treatment modalities, it enables the design of even more potent cytotoxic therapy directed into the tumor vascular bed.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001973:Bromodeoxyuridine / Q000008:administration & dosage; D002404:Catheterization; D004285:Dogs; D006499:Hepatic Artery; D007260:Infusion Pumps; D008099:Liver / Q000000981:diagnostic imaging; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000188:drug therapy; D008954:Models, Biological; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D011877:Radionuclide Imaging; D013668:Technetium Tc 99m Aggregated Albumin; D013671:Technetium Tc 99m Sulfur Colloid
D000970:Antineoplastic Agents; D004364:Pharmaceutical Preparations; D013668:Technetium Tc 99m Aggregated Albumin; D013671:Technetium Tc 99m Sulfur Colloid; D001973:Bromodeoxyuridine